NCT04200573View on ClinicalTrials.gov

Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 13, 2020

Primary Completion Date

August 19, 2021

Study Completion Date

August 19, 2021

Conditions
Symptomatic Neurogenic Orthostatic HypertensionnOH
Interventions
DRUG

Ampreloxetine

The study drug will be administered orally as a single Dose A tablet

Trial Locations (2)

32809

Theravance Biopharma Investigational Site, Orlando

33014

Theravance Biopharma Investigational Site, Miami

Sponsors
All Listed Sponsors
lead

Theravance Biopharma

INDUSTRY